EcoDrugPlus

Fibroblast Growth Factor Receptor 1-Like

Ensembl ID : ENSLBEG00000003910
Gene Symbol: LOC109976786
2 Cross references
204 Possible Orthologues:

Fibroblast Growth Factor Receptor 2

Ensembl ID : ENSLBEG00000012486
Gene Symbol: FGFR2
3 Cross references
218 Possible Orthologues:

Fibroblast Growth Factor Receptor 3

Ensembl ID : ENSLBEG00000005923
Gene Symbol: FGFR3
1 Cross references
187 Possible Orthologues:

Fms Related Receptor Tyrosine Kinase 1

Ensembl ID : ENSLBEG00000017266
Gene Symbol: FLT1
3 Cross references
198 Possible Orthologues:

Folate Receptor Beta

Ensembl ID : ENSLBEG00000027860
Gene Symbol: FOLR2
3 Cross references
436 Possible Orthologues:

Free Fatty Acid Receptor 2-Like

Ensembl ID : ENSLBEG00000007520
Gene Symbol: LOC109983694
2 Cross references
338 Possible Orthologues:

Fyn Related Src Family Tyrosine Kinase

Ensembl ID : ENSLBEG00000010745
Gene Symbol: FRK
3 Cross references
202 Possible Orthologues:

Galactosidase Alpha

Ensembl ID : ENSLBEG00000004087
Gene Symbol: GLA
3 Cross references
196 Possible Orthologues:

Gamma-Aminobutyric Acid Receptor Subunit Alpha-1-Like

Ensembl ID : ENSLBEG00000017525
Gene Symbol: LOC109987284
3 Cross references
200 Possible Orthologues:

Gamma-Aminobutyric Acid Receptor Subunit Alpha-5-Like

Ensembl ID : ENSLBEG00000003336
Gene Symbol: LOC109984112
3 Cross references
195 Possible Orthologues:

Gamma-Aminobutyric Acid Receptor Subunit Alpha-6-Like

Ensembl ID : ENSLBEG00000027343
Gene Symbol: LOC109988083
3 Cross references
200 Possible Orthologues:

Gamma-Aminobutyric Acid Receptor Subunit Beta-2-Like

Ensembl ID : ENSLBEG00000004275
Gene Symbol: LOC109993506
3 Cross references
200 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).